Watch now (4 min) | Equally as worrying, “Cardiovascular manifestations were found in 29.24% of patients.”
When Pfizer and Moderna went for full FDA approval, they received from the FDA a Biological Licensing Agreement (BLA) letter, essentially stating, “You must study myocarditis with your vaccines.”
What that entails, explained Dr. Peter McCullough, is prospective cohort studies, meaning you measure everything (troponin levels, EKG, echocardiogram, ultrasound, etc.) at baseline, give the vaccine, and compare the results from before and afterwards.
But surprise, surprise, they never did those studies.
However, Mansanguan & Colleagues from Thailand did — and the data is alarming.
Their study had a total of 301 children aged 13 to 18. They screened each person’s cardiovascular baseline via troponin levels, EKGs, echocardiograms, ultrasounds of the heart, etc. — gave two doses of the Pfizer vaccine, and repeated everything afterwards.
“And here’s the bombshell.”
They came up with a suspected myopericarditis rate of 2.33%.
• “Seven participants (2.33%) exhibited at least one elevated cardiac biomarker or positive lab assessments.”
• Equally as worrying, “Cardiovascular manifestations were found in 29.24% of patients, ranging from tachycardia or palpitation to myopericarditis.”
• “Myopericarditis was confirmed in one patient after vaccination. Two patients had suspected pericarditis and four patients had suspected subclinical myocarditis.”
“This is [23,300] cases per million!” exclaimed Dr. McCullough.
Video and more at direct link.